IntelGenx Technologies (IGXT) Stock Price, News & Analysis

Company Overview

IntelGenx Technologies (OTCMKTS:IGXT) is a Canadian specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. The company’s proprietary VersaFilm® platform enables the formulation of active pharmaceutical ingredients into oral transmucosal films that provide precise dosing and rapid onset of action. IntelGenx leverages this technology to address therapeutic needs across pain management, central nervous system disorders and other therapeutic areas, positioning itself as a leader in thin‐film drug delivery solutions.

In addition to its in‐house product pipeline, IntelGenx offers contract development and manufacturing services to pharmaceutical and biotechnology partners seeking to utilize its film technology. Its expertise spans formulation development, analytical testing, scale‐up and regulatory support. The company operates fully equipped facilities in Montreal, Canada, and Bydgoszcz, Poland, ensuring global capacity for clinical and commercial manufacturing.

Throughout its history, IntelGenx has forged strategic collaborations with academic institutions, contract research organizations and multinational pharmaceutical firms to advance product candidates through preclinical and clinical stages. The company’s product portfolio includes both proprietary assets and out‐licensed programs that leverage the convenience and patient compliance advantages of oral film delivery. IntelGenx films are designed to dissolve quickly on the tongue or buccal mucosa, eliminating the need for water and improving ease of use.

Under the leadership of Chief Executive Officer James Joyce and a management team with extensive experience in pharmaceutical development and commercialization, IntelGenx has evolved from a research‐focused spin‐off to a contract partner and product innovator serving markets in North America, Europe and Asia. The company remains dedicated to expanding its film technology applications and advancing treatments that improve patient outcomes.

Key Stats

• Today's Range: $0.17 to $0.17
• 50-Day Range: $0.17 to $0.17
• 52-Week Range: $0.09 to $0.22
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $29.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IGXT Stock Analysis - Frequently Asked Questions

How have IGXT shares performed this year?

IntelGenx Technologies' stock was trading at $0.1670 at the beginning of 2025. Since then, IGXT shares have increased by 0.0% and is now trading at $0.1670.

How were IntelGenx Technologies' earnings last quarter?

IntelGenx Technologies Corp. (OTCMKTS:IGXT) issued its quarterly earnings results on Thursday, November, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.02) by $0.01. The firm had revenue of $0.51 million for the quarter.

How do I buy shares of IntelGenx Technologies?

Shares of IGXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IntelGenx Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IntelGenx Technologies investors own include Pfizer (PFE), Tesla (TSLA), Advanced Micro Devices (AMD), Ford Motor (F), Rithm Capital (RITM), Rolls-Royce Holdings PLC (RYCEY) and Blink Charging (BLNK).

Company Calendar

• Last Earnings: 11/12/2020
• Today: 7/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IGXT
• CIK: 1098880
• Web: www.intelgenx.com
• Phone: (514) 331-7440
• Fax: 514-331-0436
• Employees: 38
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.04 million
• Price / Sales: 28.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -2.39

Miscellaneous

• Outstanding Shares: 174,658,000
• Free Float: 101,214,000
• Market Cap: $29.17 million
• Optionable: Not Optionable
• Beta: 2.47